Viracta CFO/COO Dan Chevallard resigns; Melody Burcar appointed interim CFO

Viracta Therapeutics, Inc.

Dan Chevallard resigns as CFO and COO effective March 20, 2024 to pursue other opportunities; no disagreement with company.
Melody Burcar appointed interim principal financial officer and principal accounting officer; previously SVP of Finance.
Burcar receives annual base salary of $340,000, target bonus of 35%, and stock option grant of 100,000 shares at $0.99/share.
Chevallard enters consulting agreement at $375/hour for up to 8 hours/month for up to 6 months; options/RSUs continue vesting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dan Chevallard

Chief Financial Officer and Chief Operating Officer

Viracta Therapeutics, Inc.

Effective: 2024-03-20
Successor: Melody Burcar
Filed: March 20, 2024, 7:59 PM ET

On March 15, 2024, Dan Chevallard informed Viracta Therapeutics, Inc. (the “Company”) that he was resigning from his positions as Chief Financial Officer and Chief Operating Officer of the Company, effective on March 20, 2024, to pursue other opportunities.

Role change

Melody Burcar

Senior Vice President of Finance

Viracta Therapeutics, Inc.

Effective: 2024-03-18
Filed: March 20, 2024, 7:59 PM ET

Melody Burcar, MBA, CPA, 41, was promoted to the Company’s Senior Vice President of Finance, effective March 18, 2024

Appointed (interim)

Melody Burcar

interim principal financial officer and interim principal accounting officer

Viracta Therapeutics, Inc.

Effective: 2024-03-20
Filed: March 20, 2024, 7:59 PM ET

Effective upon Mr. Chevallard’s resignation as Chief Financial Officer and Chief Operating Officer, Melody Burcar, the Company’s Senior Vice President of Finance, will serve as the Company’s interim principal financial officer and interim principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Chevallard.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dan Chevallard resigned as Chief Financial Officer and Chief Operating Officer at Viracta Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer and Chief Operating Officer

Exact text from the filing

On March 15, 2024, Dan Chevallard informed Viracta Therapeutics, Inc. (the “Company”) that he was resigning from his positions as Chief Financial Officer and Chief Operating Officer of the Company, effective on March 20, 2024, to pursue other opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..

Action: promoted
Role: Senior Vice President of Finance

Exact text from the filing

Melody Burcar, MBA, CPA, 41, was promoted to the Company’s Senior Vice President of Finance, effective March 18, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Melody Burcar was appointed as interim principal financial officer and interim principal accounting officer at Viracta Therapeutics, Inc..

Action: appointed
Role: interim principal financial officer and interim principal accounting officer

Exact text from the filing

Effective upon Mr. Chevallard’s resignation as Chief Financial Officer and Chief Operating Officer, Melody Burcar, the Company’s Senior Vice President of Finance, will serve as the Company’s interim principal financial officer and interim principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Chevallard.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-034230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.